HPV therapeutic nucleic acid vaccine

The nucleic acid sequences provided by the present invention comprises sequence HPV16-AVLS1 and sequence HPV16-AVLC1 in a 1:1 ratio; and sequence HPV18-AVLS1 and sequence HPV18-AVLC1 in a 1:1 ratio; the sequence AVLS1 and the sequence AVLC1 comprise two concatenated E6 proteins, two LI short peptides, two L2 short peptides, two concatenated E7 proteins, one PADRE sequence, and one adjuvant sequence respectively; the N-terminal of sequence AVLS1 carries a mouse IgK secretion peptide sequence; the N-terminal of sequence AVLC1 carries a ubiquitin sequence. The nucleic acid sequences provided by the present invention can not only induce high titer antibodies against E6/E7, but also elicit a high level of functional cellular immune, demonstrating excellent preventive and therapeutic effects against tumors related to HPV..

Medienart:

Patent

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Europäisches Patentamt - (2024) vom: 27. Feb. Zur Gesamtaufnahme - year:2024

Sprache:

Englisch

Beteiligte Personen:

ZHANG XIUJUN [VerfasserIn]
LIU LEI [VerfasserIn]
TANG JIANMING [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
bio
C12N: Microorganisms or enzymes; compositions thereof; pr (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2024-02-27, Last update posted on www.tib.eu: 2024-03-17, Last updated: 2024-03-22

Patentnummer:

US11911455

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA00090452X